NASDAQ:OMER Omeros (OMER) News Today $2.99 +0.05 (+1.70%) (As of 09/25/2023 ET) Add Compare Share Share Today's Range$2.84▼$2.9950-Day Range$2.81▼$5.6952-Week Range$1.74▼$7.80Volume267,368 shsAverage Volume681,944 shsMarket Capitalization$187.94 millionP/E Ratio4.67Dividend YieldN/APrice Target$8.00 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineContrasting Allarity Therapeutics (NASDAQ:ALLR) & Omeros (NASDAQ:OMER)americanbankingnews.com - September 16 at 1:30 AMBarclays PLC Grows Stock Holdings in Omeros Co. (NASDAQ:OMER)marketbeat.com - August 30 at 4:17 AMOmeros: Where Medical Hopes Tangle With Fiscal Ropesmsn.com - August 24 at 7:01 PMOmeros: Betting Big On Narsoplimab, We Are Still A Buyermsn.com - August 23 at 9:41 AMInstitutions own 40% of Omeros Corporation (NASDAQ:OMER) shares but individual investors control 56% of the companyfinance.yahoo.com - August 15 at 9:23 AMOmeros GAAP EPS of -$0.70 misses by $0.13msn.com - August 9 at 9:47 AMOmeros Corporation Reports Second Quarter 2023 Financial Resultsfinance.yahoo.com - August 9 at 9:47 AMOmeros Q2 2023 Earnings Previewseekingalpha.com - August 8 at 6:45 PMOmeros (NASDAQ:OMER) Upgraded by StockNews.com to "Hold"marketbeat.com - August 4 at 9:15 PMOmeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023finance.yahoo.com - August 4 at 6:30 PMOmeros Corporationmoney.usnews.com - July 25 at 1:57 PMOmeros Co. Forecasted to Earn FY2024 Earnings of ($2.06) Per Share (NASDAQ:OMER)marketbeat.com - July 14 at 7:22 AMMonoclonal Antibodies Industry Analysis 2023: 180+ Companies, 230+ Drugs, Therapeutics Assessment, Inactive Pipeline Products, Unmet Needsfinance.yahoo.com - June 26 at 7:51 AMGlobal Monoclonal Antibodies Market Landscape Assessment 2023: Developments, Trends, Competitors and Productsfinance.yahoo.com - June 23 at 2:24 PMOmeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congressfinance.yahoo.com - June 12 at 7:43 PMWhy Shares of Omeros Dropped on Mondayfinance.yahoo.com - June 12 at 7:43 PMOmeros Co. (NASDAQ:OMER) Holdings Lifted by Cambridge Investment Research Advisors Inc.marketbeat.com - June 2 at 4:42 AMOMER, TWST and RXTR are among after hour moversseekingalpha.com - June 1 at 9:25 PMOmeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congressfinance.yahoo.com - June 1 at 4:25 PMUnusual Call Option Trade in Omeros (OMER) Worth $30.00Kmsn.com - May 17 at 8:50 PMOmeros: Q1 Earning Overview, Best Contrarian Biotech Play Of 2023msn.com - May 16 at 8:04 PMOmeros Q1 2023 Earnings Previewmsn.com - May 11 at 12:57 AMEarnings Preview: Omerosmsn.com - May 11 at 12:57 AMOmeros: Q1 Earnings Snapshotapnews.com - May 11 at 12:57 AMOmeros: Q1 Earnings Insightsmsn.com - May 11 at 12:57 AMOmeros Stock (NASDAQ:OMER), Dividendsbenzinga.com - May 10 at 7:57 PMOmeros Corporation Reports First Quarter 2023 Financial Resultsfinance.yahoo.com - May 9 at 6:55 PMOmeros (OMER) Set to Announce Earnings on Tuesdaymarketbeat.com - May 5 at 9:46 AMOmeros Corporation to Announce First Quarter Financial Results on May 9, 2023finance.yahoo.com - May 4 at 7:03 PMOmeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuriafinance.yahoo.com - April 25 at 10:53 AMOmeros lands $6.7M grant to test treatment for cocaine addictionbizjournals.com - April 12 at 10:00 AMOmeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Programfinance.yahoo.com - April 10 at 9:47 AMQ4 2022 Omeros Corp Earnings Callfinance.yahoo.com - March 14 at 4:36 PMOmeros Corporation (NASDAQ:OMER) Q4 2022 Earnings Call Transcriptfinance.yahoo.com - March 14 at 4:36 PMOmeros stock climbs amid Q4 Omidria royalty revenue; eyes FDA refiling for narsoplimabseekingalpha.com - March 14 at 12:21 PMOmeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Resultsfinance.yahoo.com - March 13 at 7:03 PMOmeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bankfinance.yahoo.com - March 10 at 6:11 PMOmeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023finance.yahoo.com - March 7 at 9:18 AMWhy Omeros Stock Bolted Higher This Weekfinance.yahoo.com - February 9 at 6:11 PMWhy Omeros Corporation Stock Is Skyrocketing Todayfinance.yahoo.com - February 6 at 4:35 PMOmeros Corporation Receives $200 Million Milestone Payment from Rayner Surgicalfinance.yahoo.com - February 6 at 10:28 AMParse Biosciences moves into new South Lake Union spacebizjournals.com - January 23 at 5:43 AMPlasminogen Market 2023 : Recent Developments, Industry Trends and Investigation Growth Rate, and Forecast to 2028marketwatch.com - January 15 at 5:24 AMPNH and aHUS Market Massive Growth Strikes Due To Technological Innovation During 2023-2028marketwatch.com - January 12 at 8:42 AMComplement Drug Market 2023 Statistics, Share Price, Growth Prospects, Industry Trends till 2029marketwatch.com - January 11 at 10:45 PMComplement Drug for Kidney Disease Market Global and Regional Analysis and Forecast 2028marketwatch.com - January 5 at 8:44 AMOmeros' Deafening Silenceseekingalpha.com - December 27 at 1:14 AMOmeros Target of Unusually Large Options Trading (NASDAQ:OMER)marketbeat.com - December 23 at 11:57 AM5 Cheapest Stocks With Biggest Upsideinsidermonkey.com - December 19 at 12:53 PMPlasminogen Market 2023 : Trends, Industry Structure, Development, Demographics, Developing Factors By 2028marketwatch.com - December 13 at 7:45 AM Get Omeros News Delivered to You Automatically Sign up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter. Email Address OMER Media Mentions By Week OMER Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OMER News Sentiment▼0.000.50▲Average Medical News Sentiment OMER News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OMER Articles This Week▼01▲OMER Articles Average Week Get Omeros News Delivered to You Automatically Sign up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NKTR News PRTK News ASMB News EBS News IVA News PRAX News EGRX News RIGL News XOMA News ALLK News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:OMER) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omeros Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.